Anti-inflammatory Action of the Treated-Yeast, Milmed, Under IBS-IBD Conditions

IF 1.1 Q4 ALLERGY
T. Archer
{"title":"Anti-inflammatory Action of the Treated-Yeast, Milmed, Under IBS-IBD Conditions","authors":"T. Archer","doi":"10.37191/mapsci-2582-6549-3(1)-032","DOIUrl":null,"url":null,"abstract":"In order to assess the anti-inflammatory and therapeutic action of the probiotic, treated-yeast Milmed, twelve patients (age range 25-to-79 years) presenting IBS-IBD with a wide range of gut-intestinal symptoms, were studied. Each patient completed a questionnaire outlining demographic characteristics and test items regarding their health issues, both prior to and after the twelve-week period (on three occasions each week) of Milmed intervention. Patients’ accounts of their symptom-profiles were quantified and subjected to statistical analyses. It was observed that in comparison with the placebo (administered untreated-yeast) control, the Milmed group reported fewer symptoms, following treatment, as well as also fewer symptoms compared to their pre-treatment report. Untreated-yeast administration to patients did not induce any reduction of IBS-IBD symptoms. There was no correlation between patients’ responses regarding symptoms Before and After intervention. It is possible that increasing the number of capsules ingested per week, from 3/week to 1/day, may have provided the patients with greater benefits. Despite certain limitations of this study when taken together with the reported anti-inflammatory propensity of Milmed upon glial and neuronal cell cultures in vitro, these findings imply several useful therapeutic applications for the treated-yeast, Milmed, in the treatment of gut-intestinal conditions, such as IBS-IBD and other related ailments.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37191/mapsci-2582-6549-3(1)-032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1

Abstract

In order to assess the anti-inflammatory and therapeutic action of the probiotic, treated-yeast Milmed, twelve patients (age range 25-to-79 years) presenting IBS-IBD with a wide range of gut-intestinal symptoms, were studied. Each patient completed a questionnaire outlining demographic characteristics and test items regarding their health issues, both prior to and after the twelve-week period (on three occasions each week) of Milmed intervention. Patients’ accounts of their symptom-profiles were quantified and subjected to statistical analyses. It was observed that in comparison with the placebo (administered untreated-yeast) control, the Milmed group reported fewer symptoms, following treatment, as well as also fewer symptoms compared to their pre-treatment report. Untreated-yeast administration to patients did not induce any reduction of IBS-IBD symptoms. There was no correlation between patients’ responses regarding symptoms Before and After intervention. It is possible that increasing the number of capsules ingested per week, from 3/week to 1/day, may have provided the patients with greater benefits. Despite certain limitations of this study when taken together with the reported anti-inflammatory propensity of Milmed upon glial and neuronal cell cultures in vitro, these findings imply several useful therapeutic applications for the treated-yeast, Milmed, in the treatment of gut-intestinal conditions, such as IBS-IBD and other related ailments.
IBS-IBD条件下发酵酵母的抗炎作用
为了评估益生菌治疗酵母Milmed的抗炎和治疗作用,研究了12例(年龄25- 79岁)患有多种肠道症状的IBS-IBD患者。每位患者完成了一份问卷,概述了在12周(每周三次)Milmed干预之前和之后的人口统计学特征和有关其健康问题的测试项目。对患者的症状描述进行量化并进行统计分析。观察到,与安慰剂(给予未经处理的酵母)对照组相比,Milmed组在治疗后报告的症状较少,与治疗前报告的症状相比也较少。未经处理的酵母菌给药没有引起IBS-IBD症状的任何减轻。干预前后患者对症状的反应无相关性。增加每周服用胶囊的数量,从每周3次增加到每天1次,可能会给患者带来更大的益处。尽管本研究有一定的局限性,当结合报道的Milmed在体外培养的胶质细胞和神经元细胞上的抗炎倾向时,这些发现表明,经过处理的酵母Milmed在治疗肠道疾病(如IBS-IBD和其他相关疾病)方面有一些有用的治疗应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.60
自引率
10.00%
发文量
69
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信